TOPADUR, Yonsei University and Juvic Inc. grant awarded

Zurich-Schlieren, Switzerland, 2 November 2023

We are pleased to announce that TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with partners from Yonsei University and Juvic Inc. in South Korea. The project aims to develop new technologies for the treatment of systemic sclerosis. We thank Innosuisse and the Korea Institute for Advancement of Technology (KIAT) for their support.

Download DocumentDokument herunterladen
Press Release

TOPADUR submits an Orphan Drug Designation application for TOP-N53

TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.

Read more

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

The Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.

Read more

Scientific Publication in Advanced Therapeutics

Dual-Mode Vasodilator M119 Delivery to Hair Follicle via Dissolving Microneedle for Advanced Alopecia Treatment.

Read more